Gene or Genome – Page 19

Alumis Files for IPO to Fund Phase 3 Studies for Second-Generation TYK2 Inhibitor

11 months ago talkbio0Tagged Alumis, immune-mediated diseases, Immunology, Inhibitor, IPO, Phase 3 studies, Precision - temporal, TYK2, TYK2 gene

Alumis, IPO, TYK2 inhibitor, Phase 3 studies, immune-mediated diseases, biotech, precision immunology

Moon Surgical’s Maestro Robotic Laparoscopy Platform Receives FDA Clearance for Commercial Use

11 months ago talkbio0Tagged Clearance, commercial, Moon Surgical, MRO gene, Robotic Laparoscopy, Surgical Innovation, United States Food and Drug Administration, utilization qualifier

Moon Surgical, Maestro, Robotic Laparoscopy, FDA Clearance, Commercial Use, Surgical Innovation

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

11 months ago talkbio0Tagged actinium-225, Authority, BlackRock, cancer pipeline, Gastro-enteropancreatic neuroendocrine tumor, Investments, Isotopes, medical radioisotopes, Munich, Qatar, Radiopharmaceuticals, SLC22A18 gene, Technology, Temasek

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Bristol Myers’ KRAS Confirmatory Data Avoid Amgen’s Flaws but Leave FDA Prospect Unclear

11 months ago talkbio0Tagged Accelerated, amgen, approval pathway, clinical benefits, confirmatory data, confirmatory trials, K-ras Oncogene, Myers, oncology therapies, squibb, United States Food and Drug Administration

Bristol Myers Squibb, KRAS confirmatory data, Amgen, FDA, accelerated approval pathway, oncology therapies, clinical benefits, confirmatory trials

Akeso and Summit’s Keytruda-Topping Results in NSCLC Generate Significant Interest at ASCO

11 months ago talkbio0Tagged Akeso, ASCO, Ivonescimab, Keytruda, Malignant Neoplasms, Non-Small Cell Lung Carcinoma, PDCD1 gene, summit, Vascular Endothelial Growth Factor A

Akeso, Summit, Keytruda, NSCLC, ASCO, Merck, Ivonescimab, PD-1, VEGF, Cancer Treatment

Lilly Strengthens Neuro Pipeline with $45M Deal for QurAlis’ Preclinical ALS and Dementia Treatment

11 months ago talkbio0Tagged ALS, Amyotrophic Lateral Sclerosis, Eli Lilly, neuro pipeline, Neurodegenerative Disorders, Oligonucleotides, preclinical treatment, Presenile dementia, QRL-204, QurAlis, splice-switching antisense, UNC13A gene

Lilly, QurAlis, ALS, dementia, neurodegenerative diseases, UNC13A, splice-switching antisense oligonucleotide, QRL-204, neuro pipeline, preclinical treatment

BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati

11 months ago talkbio0Tagged Accelerated, Approved, Confirmatory Trial, Inhibitor, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, Pharmacotherapy, Progression-Free Survival, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA

CSL Seqirus Secures Fourth US Award to Enhance Bird Flu Vaccine Stockpile

11 months ago talkbio0Tagged Aves, BARDA, bird flu vaccine, CSHL1 gene, Government, Influenza in Birds, pandemic preparedness, public health protection, Seqirus, U.S., Vaccines

CSL Seqirus, bird flu vaccine, US government award, BARDA, pandemic preparedness, avian influenza, H5N1, vaccine stockpile, public health protection

Immunovant Shifts Focus to Next-Generation FcRn Inhibitor IMVT-1402, Delaying Batoclimab Development ###

11 months ago talkbio0Tagged Autoimmune Diseases, Batoclimab, Biological Factors, FCGRT gene, FcRn, Immunovant, IMVT-1402, Inhibitor, Roivant

Immunovant, IMVT-1402, FcRn inhibitor, Batoclimab, Autoimmune diseases, Vyvgart, Roivant, Biopharmaceuticals

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

11 months ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis